{"id":904624,"date":"2025-11-03T18:18:05","date_gmt":"2025-11-03T23:18:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-upcoming-investor-conferences\/"},"modified":"2025-11-03T18:18:05","modified_gmt":"2025-11-03T23:18:05","slug":"pyxis-oncology-to-participate-in-upcoming-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-upcoming-investor-conferences\/","title":{"rendered":"Pyxis Oncology to Participate in Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">BOSTON, Nov.  03, 2025  (GLOBE NEWSWIRE) &#8212; Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that management will participate in the following upcoming investor conferences in November 2025:<\/p>\n<ul>\n<li>\n          <strong>Guggenheim 2<\/strong><br \/>\n          <sup><br \/>\n            <strong>nd<\/strong><br \/>\n          <\/sup><br \/>\n          <strong> Annual Healthcare Innovation Conference<\/strong>, Boston, MA, Monday, November 10, 2:30 p.m. ET. \u2013 Fireside chat.<\/p>\n<\/li>\n<li>\n          <strong>Stifel 2025 Healthcare Conference<\/strong>, New York, NY, Tuesday, November 11, 4:00 p.m. ET. \u2013 Fireside chat.<\/p>\n<\/li>\n<\/ul>\n<p align=\"left\">Live webcasts and replays of the Guggenheim and Stifel fireside chats will be available on the Events &amp; Presentations page in the Investor Relations section of Pyxis Oncology\u2019s website, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=bwud_qlu7djaIUU3c5q9QfufScwVK74yzuuIFkgTjCBQCpOME25SJfb5Qw_lBly6Rw2zFLp2lUjmfH-xgOHQXMu0NGAHVkzcHswI3gVcRr8=\" rel=\"nofollow\" target=\"_blank\">ir.pyxisoncology.com<\/a>.<\/p>\n<p align=\"left\">\n        <strong>About Pyxis Oncology, Inc.<\/strong><br \/>\n        <br \/>Pyxis Oncology, Inc. is a clinical stage biopharmaceutical company developing therapeutics for difficult-to-treat cancers. The Company\u2019s lead candidate, micvotabart pelidotin (MICVO), is a first-in-concept antibody drug conjugate (ADC) that targets extradomain-B of fibronectin (EDB+FN), a non-cellular structural component of the tumor extracellular matrix (ECM). EDB+FN is selectively overexpressed in the tumor microenvironment of a wide range of solid tumors and largely absent from normal adult tissues. MICVO is designed to treat solid tumors through a three-pronged mechanism of action: direct tumor cell killing, bystander effect and immunogenic cell death. MICVO is currently being evaluated in Phase 1 clinical studies in patients with recurrent and metastatic head and neck squamous cell carcinoma (R\/M HNSCC) and other solid tumors, both as monotherapy and in combination with Merck\u2019s anti-PD-1 therapy, KEYTRUDA\u00ae (pembrolizumab). Pyxis Oncology is focused on advancing MICVO, with the goal of improving outcomes for patients living with R\/M HNSCC and contributing to meaningful progress in cancer treatment.<\/p>\n<p align=\"left\">To learn more, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WZK0gpi1H1Rt6P2X8yBSXkyHgCId085zBHuz5ZLJ-VFq3HQg9UEUM2lSDPZhP9Yf-exKmlpyMWc00JV1ari0xrw74Mu0kda0WKb7RPpSDyc8_rUDDYl5YePhu6FnUrWE3tpXDtgWOPmOMJ7Iac0pyYjXh-AvKQsT3npiZPG7gvl96NKyZmrzI5-bdVgAi4YIwnJj4ev5WFBJRexK8rntH8KpRqWHZVurIPkBVxDairmEDiGYh-vAC9zB1dXjD2lUYFQQsZUDPYTnj2m0KnXkFA==\" rel=\"nofollow\" target=\"_blank\">www.pyxisoncology.com<\/a>\u00a0or follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zXRp2pJlunvp5XUhPlhZ4ILAkjv_dp8ZC-LzhPZUhLZnxoKhhIQfiUhns92lhEVYDGsK5ZeTTK7kV-7k-dNEp0eq2NdnMZ1HiZlyvYCqRGZVUxe4QEIQB9gJw9eXtFX_S7PePboBOtB80xe0WiI8F8Ykmd1nyPfMU76Rad_rA1XB-nZUXpggbUG18mRAIGDAPZCk53HICIilPyNMvKR0E8Q2p2EUW_EBkiaN-gMjCXghK3NyQbU-mESKdv4o-Rem\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p align=\"left\">\n        <strong>Pyxis Oncology Contact<\/strong><br \/>\n        <br \/>Alex Kane<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DufjblPzYjHYkgc7lNjQ7PPdPscQB3nJ3w0bk4S1vtx133H7--VLoc5dyjyIpBOFDciDJ3h21eGceF5qnb_xxRmwXPsWulGHJ9VBF5Xtwcyj7w07e8PWIUlRA4RkDsm7Im971x_Ctv5SsM4AHyQkyOzgkkbAx9aFsXZvQ-BUQN_5IP_Wj_1wGnnwA1LGBZSGS5DMUlq7rKX2vdwcZWl7LGKAF8jc1zkaHtYqaMSdUBHC6-NYHi9cPE3T37EmWXKOwiRuXSKlws8CNq8Ub2AbBbX8GES8oaanoc7BqBUqhoFsFJLVKX7xKTOgWDdD_p5PRRDyvipV5jss0yIY7P0267PAekficrawDsaqAAHahmX2XXcFYE3lX5eGCyUGAKhRIpct_EAllUNAMe7OwfmAvJkcBhmZxEx7YrC0Gp4jWiHbBVmU0hmgBY5S52v15qpfqmS3P-VNOy4TZJzZyC0M34YPan4RwtbXCsYpjcEosxujMoup5UFeKZJX2UYaM3-C\" rel=\"nofollow\" target=\"_blank\">IR@pyxisoncology.com<\/a><\/p>\n<p align=\"left\">\n        <strong>Media<\/strong><br \/>\n        <br \/>Cailyn McCutcheon<br \/>Real Chemistry<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=R17DL3gvDp29DX8IlEFWbu9TvQXZts7zcL9Kt2A3F3aX2HRVW5snTLC6rNC7gR4VTOSVJmHwEkylps6CWCpd3dqXCMyI5ibaj2q7UtIGL8TOF7jIcgOn0q63Oi5b_SMZ\" rel=\"nofollow\" target=\"_blank\">cmccutcheon@realchemistry.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NzM3NiM3MjQwMjE2IzIyMDkyMjk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NTYzZDg0MmEtMDM5MC00ZGU3LWIxYWEtMDI1Njg1YjJhZDJmLTEyMjA3ODItMjAyNS0xMS0wMy1lbg==\/tiny\/Pyxis-Oncology.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) &#8212; Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that management will participate in the following upcoming investor conferences in November 2025: Guggenheim 2 nd Annual Healthcare Innovation Conference, Boston, MA, Monday, November 10, 2:30 p.m. ET. \u2013 Fireside chat. Stifel 2025 Healthcare Conference, New York, NY, Tuesday, November 11, 4:00 p.m. ET. \u2013 Fireside chat. Live webcasts and replays of the Guggenheim and Stifel fireside chats will be available on the Events &amp; Presentations page in the Investor Relations section of Pyxis Oncology\u2019s website, ir.pyxisoncology.com. About Pyxis Oncology, Inc. Pyxis Oncology, Inc. is a clinical stage biopharmaceutical company developing therapeutics for difficult-to-treat cancers. The Company\u2019s &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-upcoming-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Pyxis Oncology to Participate in Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-904624","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pyxis Oncology to Participate in Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pyxis Oncology to Participate in Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) &#8212; Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that management will participate in the following upcoming investor conferences in November 2025: Guggenheim 2 nd Annual Healthcare Innovation Conference, Boston, MA, Monday, November 10, 2:30 p.m. ET. \u2013 Fireside chat. Stifel 2025 Healthcare Conference, New York, NY, Tuesday, November 11, 4:00 p.m. ET. \u2013 Fireside chat. Live webcasts and replays of the Guggenheim and Stifel fireside chats will be available on the Events &amp; Presentations page in the Investor Relations section of Pyxis Oncology\u2019s website, ir.pyxisoncology.com. About Pyxis Oncology, Inc. Pyxis Oncology, Inc. is a clinical stage biopharmaceutical company developing therapeutics for difficult-to-treat cancers. The Company\u2019s &hellip; Continue reading &quot;Pyxis Oncology to Participate in Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-03T23:18:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NzM3NiM3MjQwMjE2IzIyMDkyMjk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pyxis-oncology-to-participate-in-upcoming-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pyxis-oncology-to-participate-in-upcoming-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Pyxis Oncology to Participate in Upcoming Investor Conferences\",\"datePublished\":\"2025-11-03T23:18:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pyxis-oncology-to-participate-in-upcoming-investor-conferences\\\/\"},\"wordCount\":294,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pyxis-oncology-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NzM3NiM3MjQwMjE2IzIyMDkyMjk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pyxis-oncology-to-participate-in-upcoming-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pyxis-oncology-to-participate-in-upcoming-investor-conferences\\\/\",\"name\":\"Pyxis Oncology to Participate in Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pyxis-oncology-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pyxis-oncology-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NzM3NiM3MjQwMjE2IzIyMDkyMjk=\",\"datePublished\":\"2025-11-03T23:18:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pyxis-oncology-to-participate-in-upcoming-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pyxis-oncology-to-participate-in-upcoming-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pyxis-oncology-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NzM3NiM3MjQwMjE2IzIyMDkyMjk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NzM3NiM3MjQwMjE2IzIyMDkyMjk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pyxis-oncology-to-participate-in-upcoming-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pyxis Oncology to Participate in Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pyxis Oncology to Participate in Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-upcoming-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Pyxis Oncology to Participate in Upcoming Investor Conferences - Market Newsdesk","og_description":"BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) &#8212; Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that management will participate in the following upcoming investor conferences in November 2025: Guggenheim 2 nd Annual Healthcare Innovation Conference, Boston, MA, Monday, November 10, 2:30 p.m. ET. \u2013 Fireside chat. Stifel 2025 Healthcare Conference, New York, NY, Tuesday, November 11, 4:00 p.m. ET. \u2013 Fireside chat. Live webcasts and replays of the Guggenheim and Stifel fireside chats will be available on the Events &amp; Presentations page in the Investor Relations section of Pyxis Oncology\u2019s website, ir.pyxisoncology.com. About Pyxis Oncology, Inc. Pyxis Oncology, Inc. is a clinical stage biopharmaceutical company developing therapeutics for difficult-to-treat cancers. The Company\u2019s &hellip; Continue reading \"Pyxis Oncology to Participate in Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-upcoming-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-03T23:18:05+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NzM3NiM3MjQwMjE2IzIyMDkyMjk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-upcoming-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-upcoming-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Pyxis Oncology to Participate in Upcoming Investor Conferences","datePublished":"2025-11-03T23:18:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-upcoming-investor-conferences\/"},"wordCount":294,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NzM3NiM3MjQwMjE2IzIyMDkyMjk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-upcoming-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-upcoming-investor-conferences\/","name":"Pyxis Oncology to Participate in Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-upcoming-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NzM3NiM3MjQwMjE2IzIyMDkyMjk=","datePublished":"2025-11-03T23:18:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-upcoming-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-upcoming-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-upcoming-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NzM3NiM3MjQwMjE2IzIyMDkyMjk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NzM3NiM3MjQwMjE2IzIyMDkyMjk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-participate-in-upcoming-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Pyxis Oncology to Participate in Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/904624","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=904624"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/904624\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=904624"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=904624"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=904624"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}